表纸
市场调查报告书
商品编码
293888

兔热病:开发中产品分析

Tularaemia (Infectious Disease) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 44 Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

兔热病(tularaemia)是由一种被称为土拉杆菌(Francisella tularensis)的细菌所引起的感染病。主要是因被节肢动物(特别是扁虱和蚊子)虰咬感染。藉由皮肤、结膜囊、口腔咽喉黏膜与感染的动物及动物性物质直接接独、或摄取到被污染的食品及水、吸入被污染的灰尘粉雾而感染。主要症状有皮肤溃疡、淋巴腺肿大和疼痛、发烧、发冷等。治疗方法包含了抗生素和健康生活习惯等。

本报告提供兔热病的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等相关的系统性资讯。

目录

简介

兔热病概要

治疗药的开发

  • 开发中产品:概要
  • 各企业的开发平台
  • 大学/研究机关所开发的开发平台
  • 企业开发中的产品
  • 大学/研究机关开发中的产品

治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • Aradigm Corp
  • Arno Therapeutics Inc
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Grifols SA
  • Merck & Co Inc
  • Tetraphase Pharmaceuticals Inc

药物简介

暂停的计划

开发中止的产品

产品开发的里程碑

  • 最新消息和新闻稿

附录

图表

目录
Product Code: GMDHC13094IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Drugs In Development, 2021, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tularaemia - Overview
  • Tularaemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tularaemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tularaemia - Companies Involved in Therapeutics Development
  • Appili Therapeutics Inc
  • Aradigm Corp (Inactive)
  • DynPort Vaccine Company LLC
  • Emergex Vaccines Holding Ltd
  • EpiVax Inc
  • Tularaemia - Drug Profiles
  • ATI-1701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ciprofloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDBR-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRI-011225 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia [strain B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
  • Featured News & Press Releases
  • Sep 15, 2021: MRIGlobal expert co-authors article examining effective methods for Elusive Tularemia Vaccine
  • Dec 29, 2020: VAXIL provides update on USAMRIID and oral experiments
  • Jan 28, 2020: Researchers present positive interim data on Appili Therapeutics' ATI-1701 Biodefense program at 2020 ASM Biothreats
  • Nov 18, 2019: Researchers present new positive interim data on Appili Therapeutics ATI-1701 biodefense program at 2019 Chemical and Biological Defense Science & Technology Conference
  • Aug 20, 2019: Researchers to present new data on ATI-1701 at the 2019 Military Health System Research Symposium
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Tularaemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tularaemia - Pipeline by Appili Therapeutics Inc, 2021
  • Tularaemia - Pipeline by Aradigm Corp (Inactive), 2021
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, 2021
  • Tularaemia - Pipeline by Emergex Vaccines Holding Ltd, 2021
  • Tularaemia - Pipeline by EpiVax Inc, 2021
  • Tularaemia - Dormant Projects, 2021
  • Tularaemia - Dormant Projects, 2021 (Contd..1)
  • Tularaemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Tularaemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021